Varian Earns FDA Approval for New Radiotherapy Transponder

David Rosenfeld | | Radiology Business | Business Intelligence
Varian Medical Systems has won FDA approval for a device that improves the tracking of patient respiration during radiotherapy. The Surface Beacon® Transponder, used with the Varian Calypso system, is placed temporarily on the skin for real-time monitoring of respiration and other patient motion tracking, according to a press release. The device is said to expand the number of cancer sites where the Calypso technology can be used to monitor patients during radiotherapy. “Chest wall monitoring during treatment of the left breast can correlate with the position of the heart,” the release states. “Having a tool to monitor this position in real-time enables clinicians to design treatments that eliminate or significantly reduce dose to the heart.”

David Rosenfeld

Related Content

Orano Med breaks ground on $265M thorium production site
Image-interpretation market scoreboard: Radiologists 72%, others 28%
Lantheus lands rights to budding radiopharmaceuticals for initial outlay of $35M
17 short-term strategies to address the national radiologist shortage
‘SR’ onboards another independent practice, its 1st in the Natural State
Analysis: Allied radiology professionals generate millions of dollars per year in indirect revenues alone

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.